Seeking Alpha

It's turning out to be a good week for Isis Pharmaceuticals (ISIS +0.3%): the company forges a...

It's turning out to be a good week for Isis Pharmaceuticals (ISIS +0.3%): the company forges a partnership with AstraZeneca (AZN +0.7%) to use Isis' antisense technology to develop therapies against five cancer targets. AstraZeneca will make $31M in upfront and near-term payments, as well as further milestone, license fee and royalty payments. Yesterday, Isis said it is expanding its partnership with Biogen. (PR)
From other sites
Comments (1)
  • arthurs1
    , contributor
    Comments (358) | Send Message
     
    Another Christmas gift, what next?
    11 Dec 2012, 10:01 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs